Masimo Corporation - MASI STOCK NEWS

Masimo (NASDAQ: MASI) announced it will release its first quarter 2023 financial results after the market closes on May 9, 2023. A conference call to discuss the results will commence at 1:30 p.m. PT (4:30 p.m. ET), led by Joe Kiani, Chairman and CEO, and Micah Young, CFO. Investors can register for the call to obtain the dial-in details. The company specializes in innovative medical technology and monitoring solutions, boasting the industry-leading Masimo SET® pulse oximetry system. With over 200 million patients monitored globally, it is highly regarded in health care. However, certain products, including ORi and RPVi, have not received FDA clearance in the U.S. More about Masimo.

Masimo (NASDAQ: MASI) has announced that its Rad-G® with Temperature device has received FDA 510(k) clearance. This handheld monitor integrates SET® pulse oximetry, respiration rate from pleth (RRp®), and non-contact infrared thermometry. Its design focuses on portability and durability, making it suitable for various settings, including outpatient services and urgent care. With a battery life of 24 hours, it allows continuous monitoring. Originally developed with the Bill & Melinda Gates Foundation, the Rad-G has gained over 100 global customers. The device is set to enhance clinical assessments by providing vital signs through a single, compact tool, improving access to healthcare for five billion people lacking access to pulse oximetry.

Masimo (NASDAQ: MASI) has received De Novo clearance from the FDA for its Opioid Halo™, the first FDA-authorized solution for detecting opioid-induced respiratory depression. This breakthrough device alerts users and their loved ones about potential overdoses. Opioid Halo is cleared for over-the-counter sale for adults and children aged 15 and up, as well as prescription use. The system comprises a fingertip sensor, pulse oximeter, home hub, and smartphone app, which together monitor physiological data to detect respiratory issues and provide escalating alarms. This innovation aims to combat the opioid crisis, which caused over 80,000 accidental deaths in 2021.

Masimo (NASDAQ: MASI) has launched the Masimo Freedom™ smartwatch, a device designed to enhance personal health tracking while addressing privacy concerns. This innovative smartwatch offers continuous monitoring of key health metrics such as SpO₂, hydration index, pulse rate, and more, integrating Masimo's advanced biosensing technology. It features a unique privacy switch that halts data sharing instantly. Consumers can pre-order the smartwatch with a $100 deposit, expected to ship this fall. The launch builds on the success of the existing Masimo W1™ watch, further establishing Masimo's position in the wearable tech space.

Masimo Corporation (Nasdaq: MASI) announced major governance changes, including selecting H Michael Cohen as Lead Independent Director and plans to expand the Board from five to seven members.

The company will also seek stockholder approval to declassify the Board, allowing for one-year terms for all directors. This initiative follows consultations with stockholders, where over 50% of shares were represented in discussions.

Additionally, the Board terminated its Rights Agreement effective March 22, 2023, and has revamped its executive compensation to align better with stockholder returns by implementing multi-year performance goals.

Masimo (NASDAQ: MASI) announced that updated guidelines from the European Society of Anaesthesiology and Intensive Care (ESAIC) commend the use of its noninvasive hemoglobin monitoring technology (SpHb®) for perioperative blood management. The guidelines emphasize the advantages of continuous monitoring, allowing timely adjustments without additional blood loss. Studies cited indicate that SpHb® improves patient outcomes, reducing transfusions and mortality rates by significant margins. The ESAIC aims to update these guidelines every five years to reflect the latest evidence in managing perioperative bleeding.

Masimo (NASDAQ: MASI) announced findings from a study published in Pediatrics International, which evaluated the efficacy of its noninvasive PVi® technology in predicting fluid responsiveness for children aged 1-3 undergoing major neurosurgery. The study indicated that PVi and ∆Vpeak were effective predictors, while traditional pressure-based methods performed poorly. Out of 60 patients, 26 were identified as fluid responders, with baseline PVi showing a diagnostic accuracy AUROC of 0.775. This research highlights PVi's potential to enhance fluid management in pediatric surgery and underscores Masimo's commitment to improving outcomes for vulnerable patients.

Masimo (NASDAQ: MASI) has announced a strategic collaboration with Temple Health, focusing on remote patient monitoring and telehealth advancements. This partnership will explore the integration of Masimo's advanced technologies, including the W1™ health tracking watch and the Radius VSM™ patient monitor, to enhance healthcare delivery. They aim to improve health outcomes while raising awareness of health equity in Philadelphia. Both organizations will leverage their expertise to innovate and conduct joint clinical research. Notably, the W1™ and Radius VSM are awaiting FDA clearance, indicating potential future growth opportunities.

Masimo (NASDAQ: MASI) announced findings from a study published in the British Journal of Neurosurgery indicating that the noninvasive Pleth Variability Index (PVi) is as effective as the invasive stroke volume variation (SVV) for guiding intraoperative fluid management during neurosurgery. Conducted among 60 adult patients undergoing elective craniotomy, the study suggests PVi may be preferable given its noninvasive nature. Although fluid volume administered was higher in the SVV group (3208.3 mL vs. 2139.3 mL), other clinical outcomes like serum lactate and stay duration showed comparable results. CEO Joe Kiani emphasized PVi's cost-effectiveness and low risk.